BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25233084)

  • 1. ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
    Giannini G; Vesci L; Battistuzzi G; Vignola D; Milazzo FM; Guglielmi MB; Barbarino M; Santaniello M; Fantò N; Mor M; Rivara S; Pala D; Taddei M; Pisano C; Cabri W
    J Med Chem; 2014 Oct; 57(20):8358-77. PubMed ID: 25233084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.
    Vesci L; Bernasconi E; Milazzo FM; De Santis R; Gaudio E; Kwee I; Rinaldi A; Pace S; Carollo V; Giannini G; Bertoni F
    Oncotarget; 2015 Mar; 6(8):5735-48. PubMed ID: 25671299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
    Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
    Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
    Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
    ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinolone-based HDAC inhibitors.
    Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
    J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of adamantane based highly potent HDAC inhibitors.
    Gopalan B; Ponpandian T; Kachhadia V; Bharathimohan K; Vignesh R; Sivasudar V; Narayanan S; Mandar B; Praveen R; Saranya N; Rajagopal S; Rajagopal S
    Bioorg Med Chem Lett; 2013 May; 23(9):2532-7. PubMed ID: 23538115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the first histone deacetylase 6/8 dual inhibitors.
    Olson DE; Wagner FF; Kaya T; Gale JP; Aidoud N; Davoine EL; Lazzaro F; Weïwer M; Zhang YL; Holson EB
    J Med Chem; 2013 Jun; 56(11):4816-20. PubMed ID: 23672185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
    Zhou M; Ning C; Liu R; He Y; Yu N
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3200-3. PubMed ID: 23639537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of ST7612AA1, a Novel Oral HDAC Inhibitor, via Radical 
Thioacetic Acid Addition.
    Battistuzzi G; Giannini G
    Curr Bioact Compd; 2016 Dec; 12(4):282-288. PubMed ID: 27917100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
    Wang F; Lu W; Zhang T; Dong J; Gao H; Li P; Wang S; Zhang J
    Bioorg Med Chem; 2013 Nov; 21(22):6973-80. PubMed ID: 24095016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.
    Choi E; Lee C; Park JE; Seo JJ; Cho M; Kang JS; Kim HM; Park SK; Lee K; Han G
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1218-21. PubMed ID: 21256006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
    Cai X; Zhai HX; Wang J; Forrester J; Qu H; Yin L; Lai CJ; Bao R; Qian C
    J Med Chem; 2010 Mar; 53(5):2000-9. PubMed ID: 20143778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.
    Li X; Liu JL; Yang XH; Lu X; Zhao TT; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Jul; 20(14):4430-6. PubMed ID: 22705022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
    Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
    Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
    Yao Y; Tu Z; Liao C; Wang Z; Li S; Yao H; Li Z; Jiang S
    J Med Chem; 2015 Oct; 58(19):7672-80. PubMed ID: 26331334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
    ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.